FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W327372012> ?p ?o ?g. }

• W327372012 endingPage "52" @default.
• W327372012 startingPage "1139" @default.
• W327372012 abstract "Gliomas are malignant brain tumors, which, despite recent progress in surgical and radiological treatment, still have a poor prognosis. Since gliomas apparently resist immunological clearance mechanisms, we became interested in examining bow gliomas resist killing by the human complement system. The resistance of human cells to complement-mediated damage is, in large part, mediated by specific inhibitors of complement:membrane cofactor protein (CD46), decay-accelerating factor (CD55), and protectin (CD59). In the present study we examined the expression of complement regulators in 14 human glioma tumors and in 7 glioma cell lines (U251, U87, HS683, U373, U138, U118, and H2). Protectin was found to be strongly expressed by all glioma tumors and cell lines. Northern blotting analysis demonstrated the typical pattern of four to five protectin mRNAs in the glioma cells. Except for blood vessels, the expression of decay-accelerating factor was weak or absent in the tumors in situ, whereas in the cell lines its expression varied, ranging from negative to intermediate. Membrane cofactor protein was moderately expressed by all the cell lines but only weakly in the tumors. Cell-killing experiments demonstrated that the glioma cell lines were exceptionally resistant to C-mediated lysis. Five of the seven cell lines (U373, HS683, U118, U138, and H2) resisted complement lysis under conditions where most other cell lines were sensitive to killing. Neutralization experiments using specific monoclonal antibodies indicated that protectin was functionally the most important complement regulator in the glioma cells. The killing of the U87 and U251 cells could be significantly increased by a blocking anti-protectin monoclonal antibody, whereas for the other cell lines only moderate or no response was observed. The H2 cell line resisted killing by all antibodies and by complement. These results show that protectin is the most important complement regulator on human glioma cells. The exceptional complement resistance of some glioma cell lines suggests that they may utilize other, hitherto less well characterized, mechanisms to resist complement killing." @default.
• W327372012 created "2016-06-24" @default.
• W327372012 creator A5021937336 @default.
• W327372012 creator A5025820462 @default.
• W327372012 creator A5041922844 @default.
• W327372012 creator A5044844546 @default.
• W327372012 creator A5059097261 @default.
• W327372012 date "1996-04-01" @default.
• W327372012 modified "2023-09-23" @default.
• W327372012 title "Expression of complement membrane regulators membrane cofactor protein (CD46), decay accelerating factor (CD55), and protectin (CD59) in human malignant gliomas." @default.
• W327372012 cites W1106257837 @default.
• W327372012 cites W1481229608 @default.
• W327372012 cites W1494012470 @default.
• W327372012 cites W1505326537 @default.
• W327372012 cites W1508218366 @default.
• W327372012 cites W1523702577 @default.
• W327372012 cites W1540841707 @default.
• W327372012 cites W1598814826 @default.
• W327372012 cites W1828340002 @default.
• W327372012 cites W1866736421 @default.
• W327372012 cites W1968873650 @default.
• W327372012 cites W1997952082 @default.
• W327372012 cites W2001664656 @default.
• W327372012 cites W2007411540 @default.
• W327372012 cites W2010658984 @default.
• W327372012 cites W2035215771 @default.
• W327372012 cites W204865281 @default.
• W327372012 cites W2054975281 @default.
• W327372012 cites W2068956884 @default.
• W327372012 cites W2077019499 @default.
• W327372012 cites W2082431930 @default.
• W327372012 cites W2083708523 @default.
• W327372012 cites W2101501360 @default.
• W327372012 cites W2110108677 @default.
• W327372012 cites W2131945219 @default.
• W327372012 cites W2134812217 @default.
• W327372012 cites W2140098095 @default.
• W327372012 cites W2140971592 @default.
• W327372012 cites W2408348543 @default.
• W327372012 cites W2417329363 @default.
• W327372012 cites W62131842 @default.
• W327372012 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/1861510" @default.
• W327372012 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8644856" @default.
• W327372012 hasPublicationYear "1996" @default.
• W327372012 type Work @default.
• W327372012 sameAs 327372012 @default.
• W327372012 citedByCount "21" @default.
• W327372012 countsByYear W3273720122015 @default.
• W327372012 countsByYear W3273720122021 @default.
• W327372012 countsByYear W3273720122022 @default.
• W327372012 crossrefType "journal-article" @default.
• W327372012 hasAuthorship W327372012A5021937336 @default.
• W327372012 hasAuthorship W327372012A5025820462 @default.
• W327372012 hasAuthorship W327372012A5041922844 @default.
• W327372012 hasAuthorship W327372012A5044844546 @default.
• W327372012 hasAuthorship W327372012A5059097261 @default.
• W327372012 hasConcept C111684460 @default.
• W327372012 hasConcept C1491633281 @default.
• W327372012 hasConcept C159654299 @default.
• W327372012 hasConcept C184404459 @default.
• W327372012 hasConcept C203014093 @default.
• W327372012 hasConcept C2778227246 @default.
• W327372012 hasConcept C502942594 @default.
• W327372012 hasConcept C54355233 @default.
• W327372012 hasConcept C55493867 @default.
• W327372012 hasConcept C81885089 @default.
• W327372012 hasConcept C8487232 @default.
• W327372012 hasConcept C86803240 @default.
• W327372012 hasConcept C92731135 @default.
• W327372012 hasConcept C95444343 @default.
• W327372012 hasConceptScore W327372012C111684460 @default.
• W327372012 hasConceptScore W327372012C1491633281 @default.
• W327372012 hasConceptScore W327372012C159654299 @default.
• W327372012 hasConceptScore W327372012C184404459 @default.
• W327372012 hasConceptScore W327372012C203014093 @default.
• W327372012 hasConceptScore W327372012C2778227246 @default.
• W327372012 hasConceptScore W327372012C502942594 @default.
• W327372012 hasConceptScore W327372012C54355233 @default.
• W327372012 hasConceptScore W327372012C55493867 @default.
• W327372012 hasConceptScore W327372012C81885089 @default.
• W327372012 hasConceptScore W327372012C8487232 @default.
• W327372012 hasConceptScore W327372012C86803240 @default.
• W327372012 hasConceptScore W327372012C92731135 @default.
• W327372012 hasConceptScore W327372012C95444343 @default.
• W327372012 hasIssue "4" @default.
• W327372012 hasLocation W3273720121 @default.
• W327372012 hasOpenAccess W327372012 @default.
• W327372012 hasPrimaryLocation W3273720121 @default.
• W327372012 hasRelatedWork W143669654 @default.
• W327372012 hasRelatedWork W1981504031 @default.
• W327372012 hasRelatedWork W2024857989 @default.
• W327372012 hasRelatedWork W2062799853 @default.
• W327372012 hasRelatedWork W2086103133 @default.
• W327372012 hasRelatedWork W2089976519 @default.
• W327372012 hasRelatedWork W2104752358 @default.
• W327372012 hasRelatedWork W2802751991 @default.
• W327372012 hasRelatedWork W2894302087 @default.
• W327372012 hasRelatedWork W327372012 @default.

• next